Post a Free Blog

Submit A Press Release

Thursday, March 28, 2024
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
-- Advertisement --spot_img
HomeBusinessCWEB - FDA Declines To Approve Pfizer Biosimilar Of Roche's Cancer Drug

CWEB – FDA Declines To Approve Pfizer Biosimilar Of Roche’s Cancer Drug

silver-background-3 (9)

FDA Declines To Approve Pfizer Biosimilar Of Roche’s Cancer Drug – CWEB.com

U.S. regulators declined to approve the company’s biosimilar of Roche’s blockbuster treatment for breast cancer, Herceptin.

Biologics are produced from living cells. They are very difficult to copy with exact precision. Generic type versions of these drugs are called biosimilars.

The fate of Pfizer (PFE) is in the spotlight. Challenging times ahead for the company as “Merck Sells Consumer Business”. Pfizer stated last October it was reviewing strategic alternatives for its consumer healthcare unit and is expected to make a decision in 2018.

Pfizer (PFE) chairman and CEO Ian Read talked with Citi Group analyst Andrew Baum and stated that an acquisition of Bristol-Myers Squibb (NYSE:BMS) is off the table for now.

Other contenders for Pfizer to acquire could be I think Sangamo Therapeutics (NASDAQ:SGMO), Celgene (NASDAQ:CELG), and Madrigal Pharmaceuticals (NASDAQ:MDGL).

Celgene dominates the market with the blood cancer,Revlimid and Pomalyst. Sangamo Therapeutics in common with Bristol-Myers Squibb is that is s already a partner with Pfizer. Pfizer could easily acquire Sangamo on the cheap for them. The small biotech’s market cap is $1.6 billion. Even though they don’t have a pipeline candidate beyond early stage clinical testing, Sangamo has been in the limelight from big drug makers with the leadership in zinc finger nuclease (ZFN) gene-editing technology. Pfizer may want to hold out and see how the clinical studies progress. However, buying Sangamo sooner than later could give Pfizer a massive long-term advantage as gene therapies gain traction.

[youtube https://www.youtube.com/watch?v=9TXBP1t2rUc&w=560&h=315]

Madrigal Pharmaceuticals’ has a smaller market than Sangamo. An acquisition of the Sangamo would be relatively pretty easy for Pfizer. Buying Madrigal would give Pfizer and future with a promising drug for treating non-alcoholic steatohepatitis (NYSEARCA:NASH). The drug ready to advance to late-stage clinical development.

CWEB Analyst’s have issued a Buy Rating for  Pfizer (PFE), and a Price Target of $60 within 12 months.

Read Full Article and Videos  CWEB.com – Trending News, Blog, Shopping

Chart
PFE  data by  YCharts

 

Subscribe to get Latest News Updates

Latest News Articles

You may like more
more

Walgreens Boots Alliance Shares Gains 3 percent Following Q2 Results

Walgreens Boots Alliance (NASDAQ:WBA) shares rose more than 3%...

Home Depot to Buy SRS Distribution

Home Depot (NYSE:HD) announced its intention to purchase SRS...

Google code on Pinterest app suggests potential test of ad units, CWEB analysts say

Google and Pinterest might be testing a new partnership....

DraftKings Falls, NCAA Wants to Ban College Prop Bets. CWEB analysts issue Hold Rating on the stock.

Shares of DraftKings Inc.(DKNG) experienced a significant decline on...